Oliver D. Hantschel, PhD, Florian Grebien, Ines Kaupe^* and Giulio Superti-Furga^*

CeMM- Ctr. for Molecular Med., Vienna, Austria

M. Golam Mohi, PhD¹, Wayne W. Chan, BA^2*, Shaoguang Li, MD, PhD^3*, Benjamin Neel, MD, PhD^4* and Richard A. Van Etten, MD, PhD^5*

¹Dept. of Pharmacology, SUNY Upstate Medical University, Syracuse, NY
²Molecular Oncology Research Institute and Division of Hematology/Oncology,, Tufts Medical Center, Boston, MA
³University of Massachusetts Medical School, Worcester, MA
⁴Ontario Cancer Institute, Toronto, ON, Canada
⁵Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, Boston, MA

Lars Klemm^1*, Cihangir Duy^1*, Niklas Feldhahn^2*, John Groffen^1*, Yong-mi Kim^1*, Wolf-Karsten Hofmann, MD^3*, Hassan Jumaa^4*, Michael R Lieber^5*, Rafael Casellas^6* and Markus Muschen¹

¹Leukemia Research Program, Childrens Hospital Los Angeles, Los Angeles, CA
²Molecular Immunology, Rockefeller University, New York, NY
³MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
⁴Molecular Immunology, Max-Planck-Institute for Immunology, Freiburg, Germany
⁵University of Southern California, Los Angeles, CA
⁶National Institutes of Health,, Genomic Integrity and Immunity, NIAMS, Bethesda,, MD

Ute Brassat^1*, Stefan Balabanov^1*, Melanie Braig^1*, Daniel Bali^2*, Kerstin Borgmann^2* and Tim H. Brummendorf¹

¹Dept. of Oncology and Hematology with Sections BMT and Pneumology, Hubertus Wald-University Cancer Center, (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
²Lab. of Radiobiology & Exp. Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Satu Mustjoki, MD, PhD¹, Marja Ekblom, MD, PhD^2*, T. Petteri Arstila, MD, PhD^3*, Ingunn Dybedal, MD, PhD^4*, PK Epling-Burnette, PhD^5*, Felix Garzon, MD, PhD⁶, Tobias Gedde-Dahl, MD, PhD^4*, Sari Hernesniemi, MSc^1*, Henrik Hjorth-Hansen, MD, PhD^7*, Martin Hoglund, MD, PhD⁸, Vesa Juvonen, PhD^9*, Veli Kairisto, MD, PhD^9*, Panu Kovanen, MD, PhD^3*, Anna Kreutzman, MSc^1*, Tuisku Laurinolli^3*, Jane Liesveld, MD¹⁰, Ronald Paquette, MD¹¹, Javier Pinilla, MD, PhD⁵, Auvo Rauhala, MD, PhD^12*, Neil Shah, MD, PhD¹³, Bengt Simonsson, MD, PhD⁸, Marjatta Sinisalo, MD, PhD^14*, Juan Luis Steegmann, MD, PhD¹⁵, Leif Stenke, MD, PhD¹⁶, Jukka Vakkila, MD, PhD^3* and Kimmo Porkka, MD, PhD¹

¹Hematology Research Unit, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
²Lund University Central Hospital, Lund, Sweden
³Departments of Immunology and Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
⁴Rikshospitalet University Hospital, Oslo, Norway
⁵H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Pharmaceutical Research Institute, Wallingford, CT
⁷Department of Hematology, St. Olavs Hospital and Department of Molecular Medicine and Cancer Research, Trondheim, Norway
⁸Uppsala University Hospital, Uppsala, Sweden
⁹TYKSLAB, Turku University Central Hospital, Turku, Finland
¹⁰Univ. of Rochester Med. Ctr., Rochester, NY
¹¹Ronald Reagan UCLA Medical Center, Los Angeles, CA
¹²Vaasa Central Hospital, Vaasa, Finland
¹³University of California, San Francisco, San Francisco, CA
¹⁴Tampere University Hospital, Tampere, Finland
¹⁵Hospital Universitario de la Princesa, Madrid, Spain
¹⁶Karolinska University Hospital, Stockholm, Sweden

Gabrielle Melanie Siegers, PhD^1*, Bassim Malas Al-Beirouti, MD^1*, Alister Mark Mathieson, MSc.^1*, Tania Cristina Felizardo, PhD^2*, Simone Helke^1*, Jeffrey A. Medin, PhD² and Armand Keating, MD¹

¹Cell Therapy Program, Princess Margaret Hospital/Ontario Cancer Institute, Toronto, ON, Canada
²University Health Network, Ontario Cancer Institute, Toronto, ON, Canada

Ron Paquette, MD¹, John Nicoll^1*, Meenal Chalukya^1*, Lukasz P Gondek, MD, PhD^2*, Monika Jasek^3*, Charles Sawyers, MD^4*, Neil Shah, MD, PhD⁵ and Jaroslaw Maciejewski³

¹University of California, Los Angeles, Los Angeles, CA
²Hematologic Oncology and Blood Disorders/Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
⁴Human Oncology and Pathogenesis Program, MSKCC, Howard Hughes Medical Institute, New York
⁵University of California, San Francisco, San Francisco, CA

Richard A. Van Etten, MD, PhD¹, Wayne W. Chan, BA^1*, Virginia M. Zaleskas, MD^1*, Christoph Walz, MD^1*, Peter Evangelista, BA^1*, Katherine Lazarides, BS^1*, Monica Betancur, MS^1*, Scott Wise, MS^2*, Peter A. Petillo, PhD^2* and Daniel L. Flynn, PhD^2*

¹Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
²Deciphera Pharmaceuticals, Lawrence, KS